People with hepatitis C virus (HCV) very rarely experience a relapse of the virus following acheiving a sustained virologic response 12 weeks after completing treatment (SVR12, considered a cure), Reuters Health reports. However, certain populations of those treated for the virus are at high risk of reinfection. Publishing their findings in Clinical Infectious Diseases, researchers conducted a systematic review and meta-analysis of studies including more than 9,000 people with hep C.
The researchers looked at data from 59 studies of post-hep C cure recurrence. They sorted the data according to three groups: the low-risk group, which included those who did not have HIV (HCV monoinfected) and who had no identified risk factors for reinfection with hep C; the high-risk group, including HCV-monoinfected individuals who had at least one identified risk factor for reinfection with hep C, such as injection drug use or being incarcerated; and HIV/HCV-coinfected individuals.
The researchers estimated that the low-risk group had a post-SVR relapse rate of 0.82 per 1,000 person-years (person-years are the cumulative years participants spend in a study; this figure translates to 0.082 percent per year), and a reinfection rate of zero. This translated to a five-year risk of relapse of 0.4 percent.
Among the high-risk individuals, the late relapse rate was zero, while the reinfection rate was an estimated 19.06 per 1,000 person-years. Prisoners had the highest reinfection rate, at 45.48 per 1,000 person-years.
The coinfected individuals had a late relapse rate of zero and a reinfection rate of 32.02 per 1,000 person-years.
Overall, the five-year rate of hep C recurrence was 0.95 for the low-risk group, 10.67 percent for the high-risk group, and 15.02 percent for the coinfected group.
To read the Reuters article, click here (free registration with Medscape is required).
To read the study abstract, click here.